Home >

Welcome to ASCO Connection Discussion

The ASCO Connection Discussion forum is a space for oncology professionals and others with an interest in cancer care to ask and answer questions about every aspect of the field, from professional development advice to clinical conundrums. Everyone is welcome to participate: to ask a question or leave a response, first log in with your ASCO username and password. Please read the Discussion and Commenting Guidelines before you post a question or response. Contact our staff by email for assistance with the Discussion forum.

LOGIN TO START A DISCUSSION
Filter by Molecular Oncology Tumor Board
Molecular Oncology Tumor Board
ASCO University
May 11, 2016 9:46 AM
Read more to answer the following questions: 1) Would further imaging be required before discussing a plan for systemic therapy?  2) Which of the available tissue specimen/sites would be appropriate for HER2 testing: tissue from the primary resection specimen, metastasis from the para-aortic lymph...
Molecular Oncology Tumor Board
ASCO University
Apr 13, 2016 9:33 AM
Read more to answer the following questions: 1) What are available second line therapy options? 2)  Do you test for PD-L1 prior to recommending therapy? 3) Does smoking history affect your treatment recommendations?
Molecular Oncology Tumor Board
ASCO University
Mar 09, 2016 9:36 AM
Read more to answer the following questions: 1) What molecular testing on tissue should be performed in newly diagnosed DLBCL? 2) How need for molecular testing affects tissue requirements and biopsy size? 3) What staging studies and serum biomarkers would you obtain?  
Molecular Oncology Tumor Board
ASCO University
Feb 10, 2016 9:49 AM
Read more to answer the following questions: 1) Choice for site of biopsy? LN vs. Bone and merits/pros/cons for tissue for molecular profiling vs. confirmation of distant recurrence? 2) Would you recommend clinical genetics consultation for BRCA testing?  Expanded panel testing? 3) What additional...
Molecular Oncology Tumor Board
ASCO University
Jan 13, 2016 9:19 AM
Read more to answer the following questions: 1) What are the pathologic features that distinguish PEComa from the much more common leiomyosarcoma? 2) What is the role for cytotoxic chemotherapy in the treatment of metastatic or unresectable PEComa? 3) Are there any particular genetic targets...

Pages